{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:23Z","timestamp":1792011263393,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","award":["CAN 2014\/360"],"award-info":[{"award-number":["CAN 2014\/360"]}],"id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","award":["2017\/392"],"award-info":[{"award-number":["2017\/392"]}],"id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001424","name":"ALF","doi-asserted-by":"publisher","award":["F2014\/354"],"award-info":[{"award-number":["F2014\/354"]}],"id":[{"id":"10.13039\/100001424","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Malm\u00f6 University Hospital Cancer Research Fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.urolonc.2018.12.011","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T17:21:24Z","timestamp":1546449684000},"page":"290.e1-290.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cell-based evidence regarding the role of FSH in prostate cancer"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-4688","authenticated-orcid":false,"given":"Nishtman","family":"Dizeyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Trzybulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"Al-Jebari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilpo","family":"Huhtaniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Lundberg Giwercman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.12.011_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mce.2011.09.046","article-title":"Androgen action and metabolism in prostate cancer","volume":"360","author":"Green","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0002","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1210\/me.2010-0469","article-title":"Minireview: alternative activation pathways for the androgen receptor in prostate cancer","volume":"25","author":"Lamont","year":"2011","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2013.08.020","article-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","volume":"50","author":"Bianchini","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0006","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0007","first-page":"275","article-title":"Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group","volume":"4","author":"Garnick","year":"2000","journal-title":"Mol Urol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0008","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1464-410X.2011.10708.x","article-title":"New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist","volume":"110","author":"Garnick","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0009","first-page":"23","article-title":"The role of FSH in prostate cancer: a case report","volume":"7","author":"Catarinicchia","year":"2016","journal-title":"Urol Case Rep"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5489\/cuaj.2545","article-title":"Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer","volume":"9","author":"Hoare","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/bjc.1990.42","article-title":"Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates","volume":"61","author":"Hurkadli","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0012","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0022-5347(06)00273-4","article-title":"Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer","volume":"175","author":"Mariani","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0013","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(01)61831-7","article-title":"Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)","volume":"161","author":"Ben-Josef","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0014","first-page":"45","article-title":"The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy","volume":"28","author":"Heracek","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0015","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1001283","article-title":"Expression of follicle-stimulating hormone receptor in tumor blood vessels","volume":"363","author":"Radu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12020-008-9041-6","article-title":"Multiple facets of follicle-stimulating hormone receptor function","volume":"32","author":"Ulloa-Aguirre","year":"2007","journal-title":"Endocrine"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0017","first-page":"739","article-title":"The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology","volume":"18","author":"Simoni","year":"1997","journal-title":"Endocr Rev"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0018","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1210\/me.2007-0020","article-title":"Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation","volume":"21","author":"Wayne","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0019","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/en.2008-0850","volume":"150","author":"Alam","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/cr.2008.70","article-title":"Activation of the PI3K\/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma","volume":"18","author":"Huang","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0021","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/onc.2015.316","article-title":"Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K\/AKT\/HIF-1alpha\/cyclin D1 pathway","volume":"35","author":"Chen","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0022","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mce.2016.08.009","article-title":"LH and FSH promote migration and invasion properties of a breast cancer cell line through regulatory actions on the actin cytoskeleton","volume":"437","author":"Sanchez","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0023","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3727\/096504008786111383","article-title":"Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer","volume":"17","author":"Bose","year":"2008","journal-title":"Oncol Res"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0024","first-page":"2577","article-title":"Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer","volume":"54","author":"Thalmann","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0025","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.urology.2006.04.016","article-title":"Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression","volume":"68","author":"Ryan","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12954\/PI.13019","article-title":"Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer","volume":"1","author":"Ide","year":"2013","journal-title":"Prostate Int"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0027","doi-asserted-by":"crossref","first-page":"T87","DOI":"10.1530\/ERC-13-0470","article-title":"Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer","volume":"21","author":"Ware","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0028","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1172\/JCI96794","article-title":"Constitutively active follicle-stimulating hormone receptor enables androgen-independent spermatogenesis","volume":"128","author":"Oduwole","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0029","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.febslet.2006.03.041","article-title":"DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation","volume":"580","author":"Alimirah","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.urolonc.2018.12.011_bib0030","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/MCB.26.3.929-939.2006","article-title":"Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction","volume":"26","author":"Chen","year":"2006","journal-title":"Mol Cell Biol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918305052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918305052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:15:41Z","timestamp":1761041741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918305052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1078143918305052"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.12.011","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-based evidence regarding the role of FSH in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}